Regemat 3D

About:

REGEMAT3D, a biotech company pioneer in the use of 3D printing for regenerative therapies.

Website: http://www.regemat3d.com/

Twitter/X: regemat3D

Top Investors: Crowdcube

Description:

REGEMAT 3D is a biotech company focused on regenerative medicine and pioneer in a new and promising area called bioprinting, that uses 3D printing technologies for regenerative therapies. REGEMAT3D is a bioprinting modular system that integrates the latest advances in 3D printing and regenerative therapies to offer adapted solutions to fulfil research's needs. A tested and validated systems, it is adaptable to different types of tissues, to research the biggest unsolved biotechnology problems and to battle different kinds of pathologies, such as; Cardiovascular Disease (CVD), Peripheral Vascular Disease (PVD), Non-healing wounds, Spinal cord injury, Alzheimer´s Disease (AD), Parkinson´s Disease (PD), Musculoskeletal Disorders (MSDs), Autoimmune Disorders, Stroke, Diabetes, and Ocular Disease.

Total Funding Amount:

$1.1M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Armilla, Andalucia, Spain

Founded Date:

2015-01-01

Contact Email:

info(AT)regemat3d.com

Founders:

José Manuel Baena

Number of Employees:

11-50

Last Funding Date:

2022-03-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai